Good Day BIO: We need to act now on ag biotech

June 7, 2021
A new week—and BIO's new letter to the Biden administration on why and how we need to overcome trade barriers to agricultural biotechnology. We also look at why Black Americans are lagging behind in COVID vaccinations and what BIO proposes we do about it. (874 words, 4…
BIO

A new week—and BIO's new letter to the Biden administration on why and how we need to overcome trade barriers to agricultural biotechnology. We also look at why Black Americans are lagging behind in COVID vaccinations and what BIO proposes we do about it. (874 words, 4 minutes, 22 seconds)

 

Why we need to act now on ag biotech

 
 

Three-quarters of the American West is dealing with the worst drought in decades, threatening farmers and wildlife—yet another sign of the need for urgent climate action. Luckily, we have biotechnology that can enable more sustainable agricultural practices and help farmers respond with resilience—but many countries block this innovation.

With the threat of climate change growing by day, we need to overcome barriers to ag biotechnology, BIO President and CEO Dr. Michelle McMurry-Heath wrote in a letter sent on Friday to Agriculture Secretary Tom Vilsack and U.S. Trade Rep. Katherine Tai. 

“As you seek to position agriculture as a solution to domestic and global climate and sustainability challenges, the United States must continue to address acute and systemic trade barriers to innovative biotechnology tools in important export markets,” she said.

More Background: What to expect from the Biden administration’s agriculture policy agenda

“To fully leverage the potential of technology to address these challenges, a level-playing field globally will be essential”—particularly in these three regions: 

The European Union, where “for the first time in decades, there appear to be opportunities emerging…to enable innovation. Both the Farm to Fork strategy and the European Commission’s recent study on New Genomic Techniques point to the importance of innovation to achieving a more sustainable food system.” 

“However, significant risks remain as Europe’s regulatory processes are fundamentally prejudiced to agricultural biotechnology,” continues the letter. 

And China, which “agreed to complete regulatory review of biotechnology products within two years, on average, and to limit the scope of the regulatory review to the product’s intended use, i.e. feed or further processing.”

But: “China has failed to address either issue.” 

Then there’s Mexico, where we’ve seen “rapid dismantling of regulatory institutions and international commitments to biotechnology.” As one example, Mexico’s president issued a decree stating the intention to phase out GMO corn for human consumption by 2024 and refrain from future biotech approvals—read more. 

The bottom line: Harnessing the latest science to combat climate change will require a global strategy—one that addresses existing trade barriers in China, the EU, and Mexico and builds common ground. BIO urges the Biden administration to build a proactive trade agenda aimed at addressing existing barriers to biotechnology and facilitating regulatory approvals for critical climate technologies for agriculture.

Read and share the letter.

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 
 
 

BIO members enjoy exclusive savings with Research Solutions, the world’s leading document retrieval provider.

BIO members get 15% off on an annual subscription to Article Galaxy, Research Solutions’ award-winning SaaS research platform, simplifying literature acquisition and helping organizations save 20% on their article spend. Researchers can choose from 70 million scientific papers, across all major publishers, 24/7.

Get started with a 14-day, risk-free Enterprise trial.

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 

Vaccine disparities still exist in the U.S.—here’s what’s behind them

 
 

More than 50% of U.S. adults are fully vaccinated against COVID-19. But we can’t declare victory quite yet, because vaccination numbers still lag among one of the most vulnerable communities in the country: Black Americans. What should we do?

The Biden administration’s outreach to minority communities has “shown signs of success,”POLITICO reported yesterday, with vaccination rates among Hispanic and Asian Americans seeing “a sharp acceleration from just a month ago.”

However: “Fewer than a quarter of Black Americans had received their first COVID-19 shot as of June 3,”continues POLITICO. “Black people in several areas have accounted for an increasing proportion of COVID-19 cases and deaths,” including in D.C., where they account for nearly 90% of deaths since May 1. 

What’s going on? “Among Black people who are unsure, the most common two reasons given are worries about side effects and a desire to see how other people respond to the vaccine,” BIO’s Dr. Michelle McMurry-Heath wrote in the Washington Post in March

Listen: Voices of Vaccine Hesitancy 

Furthermore: “Inequality within our healthcare system has made Black Americans understandably distrustful of medical authorities,” Dr. Michelle wrote in the New York Daily News

This is why we need outreach programs from Black community pillarssuch as “pastors, family doctors, and other trusted local influencers—even hairstylists,” wrote Dr. Michelle in the New Jersey Star-Ledger

As part of the effort to get 70% of Americans vaccinated by July 4, the Biden administration launched Shots at the Shop, a program to engage Black-owned barbershops and beauty salons in vaccination outreach and events, we reported Friday. (Dr. Michelle and Dr. Shereef Elnahal, President of University Hospital in Newark, proposed something similar in March.)

We should be proud of how far we've come in the fight against COVID-19—but we can't and won't rest until we achieve vaccine equity both in the United States and globally. BIO will continue to focus on fighting vaccine misinformation and systemic inequity. For more information on the vaccines, visit BIO's website, www.COVIDVaccineFacts.org.
 

More Health Care News: 

Biopharma Dive: An AstraZeneca, Merck drug slows the return of genetic breast cancer
“A medicine from AstraZeneca and Merck & Co. has become the first of its type to slow the return of a particularly aggressive, hereditary form of breast cancer…researchers found Lynparza reduced the risk of disease progression or death by 42% compared to a placebo after a median of 2.5 years of follow-up.” 

Nature: A complete human genome sequence is close
“The newly sequenced genome—dubbed T2T-CHM13—adds nearly 200 million base pairs to the 2013 version of the human genome sequence.”

 
 
 
Twitter
 
LinkedIn
 
Facebook
 
 
BIO Beltway Report
BIO Beltway Report
 
Paragraph (sm) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis sample link.
 

President Biden’s Monday: Ahead of his trip to Europe, he’s meeting with NATO Secretary General Jens Stoltenberg at the White House. ICYMI: G7 finance ministers agreed to a minimum corporate tax rate of 15%, which “paves the way for levies on multinationals in countries where they make money, instead of just where they are headquartered,” Bloomberg reports

What’s Happening on Capitol Hill: “About a dozen agency heads in all are slated to speak to Congress about the budgets for their respective agencies this week,” POLITICO Pro Day Ahead tells us—stay tuned.

 
 
Paragraph (normal) - Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus sample link.
 
Twitter
 
LinkedIn
 
Facebook